QURE Stock Overview
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
uniQure N.V. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.41 |
52 Week High | US$22.48 |
52 Week Low | US$4.76 |
Beta | 0.96 |
1 Month Change | -15.20% |
3 Month Change | -20.79% |
1 Year Change | -73.23% |
3 Year Change | -83.94% |
5 Year Change | -91.00% |
Change since IPO | -62.97% |
Recent News & Updates
Recent updates
Earnings Update: uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Are Trimming Their Forecasts
Mar 03uniQure: The Valuation Got More Attractive
Feb 01Little Excitement Around uniQure N.V.'s (NASDAQ:QURE) Revenues As Shares Take 29% Pounding
Jan 17A Look At The Fair Value Of uniQure N.V. (NASDAQ:QURE)
Dec 15Revenue Downgrade: Here's What Analysts Forecast For uniQure N.V. (NASDAQ:QURE)
Aug 27Analysts Are More Bearish On uniQure N.V. (NASDAQ:QURE) Than They Used To Be
Aug 06Here's Why uniQure (NASDAQ:QURE) Can Manage Its Debt Despite Losing Money
Aug 02uniQure N.V. (NASDAQ:QURE) Looks Inexpensive After Falling 43% But Perhaps Not Attractive Enough
Jul 02Analyst Forecasts For uniQure N.V. (NASDAQ:QURE) Are Surging Higher
Jun 28uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 14Is uniQure (NASDAQ:QURE) Using Debt Sensibly?
Apr 11News Flash: 15 Analysts Think uniQure N.V. (NASDAQ:QURE) Earnings Are Under Threat
Mar 01Does uniQure (NASDAQ:QURE) Have A Healthy Balance Sheet?
Dec 09uniQure: Clinical Risk, A Critical Upcoming Catalyst And A Cash Cushion
Sep 21uniQure N.V.: 2 Possible Regulatory Approvals Makes This A Must Watch
Aug 30uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
Aug 14uniQure plunges 27% on Q2 revenue miss, postpones higher dose trial of Huntington’s disease therapy
Aug 08These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Jun 08uniQure N.V. (NASDAQ:QURE) Analysts Are Reducing Their Forecasts For This Year
May 04uniQure N.V.: Worth A Look Based On Hemophilia B Marketing Applications
Apr 08We Think That There Are Issues Underlying uniQure's (NASDAQ:QURE) Earnings
Mar 04The Consensus EPS Estimates For uniQure N.V. (NASDAQ:QURE) Just Fell Dramatically
Feb 27Is uniQure (NASDAQ:QURE) A Risky Investment?
Feb 23uniQure: Betting On Hemophilia-B Cure
Jan 18UniQure: Leading Gene Therapy Company
Nov 06These 4 Measures Indicate That uniQure (NASDAQ:QURE) Is Using Debt Safely
Oct 24How We Are Playing UniQure
Oct 04Is uniQure N.V. (NASDAQ:QURE) Trading At A 48% Discount?
Sep 19Shareholder Returns
QURE | US Biotechs | US Market | |
---|---|---|---|
7D | 3.4% | 0.9% | 0.4% |
1Y | -73.2% | 10.3% | 28.8% |
Return vs Industry: QURE underperformed the US Biotechs industry which returned 9.6% over the past year.
Return vs Market: QURE underperformed the US Market which returned 29.5% over the past year.
Price Volatility
QURE volatility | |
---|---|
QURE Average Weekly Movement | 9.3% |
Biotechs Industry Average Movement | 11.6% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.9% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: QURE's share price has been volatile over the past 3 months.
Volatility Over Time: QURE's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 480 | Matt Kapusta | https://www.uniqure.com |
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington’s disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer’s disease; and AMT-210 that is in preclinical trial to treat Parkinson’s disease.
uniQure N.V. Fundamentals Summary
QURE fundamental statistics | |
---|---|
Market cap | US$258.81m |
Earnings (TTM) | -US$308.48m |
Revenue (TTM) | US$15.84m |
16.3x
P/S Ratio-0.8x
P/E RatioIs QURE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
QURE income statement (TTM) | |
---|---|
Revenue | US$15.84m |
Cost of Revenue | US$212.60m |
Gross Profit | -US$196.75m |
Other Expenses | US$111.72m |
Earnings | -US$308.48m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -6.45 |
Gross Margin | -1,241.90% |
Net Profit Margin | -1,947.09% |
Debt/Equity Ratio | 238.8% |
How did QURE perform over the long term?
See historical performance and comparison